NCT07640893招募中2 期
A Multi-Dose, Randomized, Multicenter Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of SR604 Injection in Patients With Von Willebrand Disease
Shanghai RAAS Blood Products Co., Ltd.9 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2025年11月26日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 9
研究概览
简要总结
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in patients with von Willebrand disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet ALL of the following inclusion criteria to be enrolled:
- •Age >= 18 years and <= 65 years at the time of signing informed consent, regardless of sex;
- •At screening, patients with a confirmed diagnosis of von Willebrand disease (VWD) with documented evidence and a defined VWD subtype;
- •At least 4 new bleeding episodes within 6 months prior to screening;
- •No active bleeding symptoms prior to the first dose;
- •The subject or impartial witness fully understands and is able to comply with the protocol requirements, is willing to complete the study as planned, and voluntarily agrees to provide biological samples for testing as required by the protocol; is able to understand the procedures and methods of this clinical trial, provides voluntary participation after full informed consent, and personally signs the informed consent form.
排除标准
- •Patients meeting ANY of the following exclusion criteria will not be enrolled:
- •Known history of hypersensitivity to the investigational drug formulation or any of its components;
- •Intolerance to subcutaneous injection or presence of other local skin abnormalities or dermatological conditions that may affect drug administration and safety assessment;
- •Meeting any of the following criteria at screening:
- •Hemoglobin < 60 g/L;
- •Platelet count < 80 x 10^9/L;
- •Hepatic or renal dysfunction: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 2.5 x upper limit of normal (ULN), or total bilirubin >= 1.5 x ULN; or serum creatinine (Cr) >= 1.5 x ULN;
- •Positive for anti-human immunodeficiency virus (HIV) antibody;
- •Presence of any bleeding disorder other than von Willebrand disease [hemophilia A or B, congenital coagulation factor VII deficiency, acquired von Willebrand disease (AVWS), platelet-type VWD, inherited platelet disorders, etc.]; or significantly abnormal coagulation parameters due to diseases other than von Willebrand disease (e.g., platelet disorders, vitamin K deficiency, etc.);
- •Presence of protein C deficiency or protein S deficiency;
- •History of thrombosis or family history of thrombosis prior to signing informed consent or currently, or history of thrombophilia;
- •Severe bleeding due to VWD within 2 years prior to screening, such as intracranial hemorrhage, esophageal variceal bleeding, etc.;
- •Severe cardiac disease, such as unstable angina, congestive heart failure (New York Heart Association class >= III), severe arrhythmia (QTc interval > 500 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic blood pressure >= 160 mmHg or diastolic blood pressure >= 100 mmHg), etc.;
- •Female patients with menstrual abnormalities due to organic gynecological diseases (e.g., uterine fibroids, endometriosis, adenomyosis, etc.);
- •Previous or current life-threatening malignant neoplasms or end-stage liver disease;
- •Use of DDAVP or plasma-derived VWF-containing factor VIII concentrate, plasma-derived/recombinant VWF preparations, or antifibrinolytic therapy within 1 week prior to the first dose;
- •Use of antithrombotic agents within 1 week prior to the first dose;
- •Receipt of fresh blood/plasma or cryoprecipitate therapy within 2 weeks prior to the first dose;
- •Receipt of vaccination within 1 month prior to the first dose or planned vaccination during the study period;
- •Major surgery (major surgery defined as Grade III and IV surgeries) within 1 month prior to the first dose, or planned surgery during the study period;
- •Enrollment in other clinical trials within 1 month prior to the first dose;
- •History of drug abuse or alcohol dependence (alcohol dependence criteria: long-term drinking history exceeding 5 years, equivalent ethanol intake >= 40 g/day, or heavy drinking within 2 weeks, equivalent ethanol intake > 80 g/day. Ethanol amount (g) conversion formula = alcohol consumption (mL) x alcohol content (%) x 0.8);
- •Presence of psychiatric disease or significant mental disorder, or other reasons resulting in incapacity or lack of cognitive ability;
- •Plans for procreation or sperm donation throughout the study period up to 3 months after the last dose, or unwillingness to use effective physical contraceptive measures (e.g., condoms);
- •Presence of clinically significant disease or other reasons rendering the patient unsuitable for clinical trial participation in the investigator's opinion (e.g., patient unlikely to benefit from the clinical trial);
- •Patients whom the investigator considers to have poor compliance, rendering efficacy evaluation difficult or likelihood of completing the planned treatment course and follow-up low.
研究者
研究点 (9)
Loading locations...
相似试验
尚未招募
2 期
QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis SuppurativaNCT07417917Qilu Pharmaceutical Co., Ltd.102
尚未招募
2 期
A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)ThalassemiaNCT07579949ScinnoHub Pharmaceutical Co., Ltd.30
招募中
3 期
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia AHemophilia ANCT07416526Hoffmann-La Roche126
招募中
3 期
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia AHemophilia ANCT07416604Hoffmann-La Roche360
招募中
1 期
A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPCProstate CancerNCT07567521C Ray Therapeutics90